Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab

Area of Science:

• Neurology
• Immunology
• Rheumatology

Background:

• Adalimumab is a widely used biologic medication targeting Tumor Necrosis Factor-alpha (TNFalpha).
• It is a standard treatment for inflammatory conditions such as rheumatoid arthritis.
• TNFalpha inhibitors play a crucial role in managing autoimmune diseases.

Observation:

• A case study details a patient experiencing neurological symptoms post-adalimumab administration.
• The patient received their second dose of adalimumab for rheumatoid arthritis treatment.
• The onset of symptoms occurred shortly after the second adalimumab injection.

Findings:

• The patient likely developed Miller-Fisher syndrome, a rare neurological disorder.
• This adverse event is a potential complication following adalimumab treatment.
• The temporal association suggests a possible link between adalimumab and Miller-Fisher syndrome.

Implications:

• This case highlights the importance of monitoring for neurological side effects in patients treated with adalimumab.
• Further research may be needed to establish a definitive causal relationship.
• Clinicians should consider Miller-Fisher syndrome in the differential diagnosis for patients on TNFalpha inhibitors presenting with relevant symptoms.